{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:47:51Z","timestamp":1793364471011,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since novel strategies for prevention and treatment of metachronous peritoneal metastases (mPM) are under study, it appears crucial to identify their risk factors. Our aim is to establish the incidence of mPM after surgery for colon cancer (CC) and to build a statistical model to predict the risk of recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Retrospective analysis of consecutive pT3\u20134 CC operated at five referral centers (2014\u20132018). Patients who developed mPM were compared with patients who were PM-free at follow-up. A scoring system was built on the basis of a logistic regression model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 1423 included patients, 74 (5.2%) developed mPM. Patients in the PM group presented higher preoperative carcinoembryonic antigen (CEA) [median (IQR): 4.5 (2.5\u201313.0) vs. 2.7 (1.5\u20135.9), <jats:italic>P<\/jats:italic> = 0.001] and CA 19-9 [median (IQR): 17.7 (12.0\u201337.0) vs. 10.8 (5.0\u201321.0), <jats:italic>P<\/jats:italic> = 0.001], advanced disease (pT4a 42.6% vs. 13.5%; pT4b 16.2% vs. 3.2%; <jats:italic>P<\/jats:italic> &lt; 0.001), and negative pathological characteristics. Multivariate logistic regression identified CA 19-9, pT stage, pN stage, extent of lymphadenectomy, and lymphovascular invasion as significant predictors, and individual risk scores were calculated for each patient. The risk of recurrence increased remarkably with score values, and the model demonstrated a high negative predictive value (98.8%) and accuracy (83.9%) for scores below five.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Besides confirming incidence and risk factors for mPM, our study developed a useful clinical tool for prediction of mPM risk. After external validation, this scoring system may guide personalized decision-making for patients with locally advanced CC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12097-9","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:13:44Z","timestamp":1657026824000},"page":"7896-7906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter Cohort"],"prefix":"10.1245","volume":"29","author":[{"given":"Corrado","family":"Pedrazzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Turri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaya","family":"Spolverato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pucciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyuk","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Seog","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"issue":"1","key":"12097_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/0284186X.2014.975839","volume":"54","author":"C B\u00f6ckelman","year":"2015","unstructured":"B\u00f6ckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol (Madr). 2015;54(1):5\u201316. https:\/\/doi.org\/10.3109\/0284186X.2014.975839.","journal-title":"Acta Oncol (Madr)."},{"issue":"2","key":"12097_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00384-014-2085-6","volume":"30","author":"MAG Elferink","year":"2015","unstructured":"Elferink MAG, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JHW. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis. 2015;30(2):205\u201312. https:\/\/doi.org\/10.1007\/s00384-014-2085-6.","journal-title":"Int J Colorectal Dis."},{"issue":"1","key":"12097_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-015-1430-7","volume":"15","author":"CEL Klaver","year":"2015","unstructured":"Klaver CEL, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15(1):428. https:\/\/doi.org\/10.1186\/s12885-015-1430-7.","journal-title":"BMC Cancer."},{"issue":"3","key":"12097_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/codi.13593","volume":"19","author":"CEL Klaver","year":"2017","unstructured":"Klaver CEL, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Color Dis. 2017;19(3):224\u201336. https:\/\/doi.org\/10.1111\/codi.13593.","journal-title":"Color Dis."},{"issue":"1","key":"12097_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4096-0","volume":"18","author":"A Arjona-S\u00e1nchez","year":"2018","unstructured":"Arjona-S\u00e1nchez A, Barrios P, Boldo-Roda E, et al. HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer. 2018;18(1):1\u20138. https:\/\/doi.org\/10.1186\/s12885-018-4096-0.","journal-title":"BMC Cancer."},{"issue":"9","key":"12097_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(20)30338-7","volume":"21","author":"BJ Moran","year":"2020","unstructured":"Moran BJ. PROPHYLOCHIP: no benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2020;21(9):1124\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(20)30338-7.","journal-title":"Lancet Oncol."},{"issue":"12","key":"12097_CR7","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.ejso.2020.07.039","volume":"46","author":"H Birgisson","year":"2020","unstructured":"Birgisson H, Enblad M, Artursson S, Ghanipour L, Cashin P, Graf W. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2020;46(12):2283\u201391. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.039.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"12097_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"9","key":"12097_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Go\u00e9r\u00e9","year":"2020","unstructured":"Go\u00e9r\u00e9 D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP\u2013PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30322-3.","journal-title":"Lancet Oncol."},{"issue":"10","key":"12097_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"12","key":"12097_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3760\/cma.j.issn.1671-0274.2019.12.004","volume":"22","author":"ZY Lei","year":"2019","unstructured":"Lei ZY, Guan TP, Luo JL, Tang HS, Cui SZ. Rationality of performing hyperthermic intraperitoneal chemotherapy 5\u20138 weeks after primary tumor resection for patients with locally advanced colorectal cancer-based on COLOPEC. Zhonghua Wei Chang Wai Ke Za Zhi. 2019;22(12):1115\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.1671-0274.2019.12.004.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi."},{"key":"12097_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7800-2-3","volume":"2","author":"RL Harmon","year":"2005","unstructured":"Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:3. https:\/\/doi.org\/10.1186\/1477-7800-2-3.","journal-title":"Int Semin Surg Oncol."},{"issue":"5","key":"12097_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, MacHado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705. https:\/\/doi.org\/10.1002\/bjs.8679.","journal-title":"Br J Surg."},{"issue":"2","key":"12097_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jso.26322","volume":"123","author":"VH Le","year":"2020","unstructured":"Le VH, Thornblade L, Ituarte PHG, Lai LL, Melstrom KA. Metachronous peritoneal metastases following curative resection for colon cancer: understanding risk factors and patterns of recurrence. J Surg Oncol. 2020;123(2):622\u20139. https:\/\/doi.org\/10.1002\/jso.26322.","journal-title":"J Surg Oncol."},{"issue":"2","key":"12097_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/bjs5.50247","volume":"4","author":"S Ravn","year":"2020","unstructured":"Ravn S, Heide-J\u00f8rgensen U, Christiansen CF, Verwaal VJ, Hagemann-Madsen RH, Iversen LH. Overall risk and risk factors for metachronous peritoneal metastasis after colorectal cancer surgery: a nationwide cohort study. BJS open. 2020;4(2):284\u201392. https:\/\/doi.org\/10.1002\/bjs5.50247.","journal-title":"BJS open."},{"issue":"13","key":"12097_CR16","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1245\/s10434-020-08689-y","volume":"27","author":"AH Choi","year":"2020","unstructured":"Choi AH, Farzaneh C, Kejriwal N, et al. Rate of peritoneal carcinomatosis in resected stage II and III colon cancer. Ann Surg Oncol. 2020;27(13):4943\u20138. https:\/\/doi.org\/10.1245\/s10434-020-08689-y.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"12097_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/codi.12552","volume":"16","author":"J Segelman","year":"2014","unstructured":"Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Color Dis. 2014;16(5):359\u201367. https:\/\/doi.org\/10.1111\/codi.12552.","journal-title":"Color Dis."},{"issue":"12","key":"12097_CR18","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545\u201350. https:\/\/doi.org\/10.1046\/j.1365-2168.2002.02274.x.","journal-title":"Br J Surg."},{"issue":"6","key":"12097_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/DCR.0000000000001367","volume":"62","author":"G Baguena","year":"2019","unstructured":"Baguena G, Pellino G, Frasson M, et al. Prognostic impact of pT stage and peritoneal invasion in locally advanced colon cancer. Dis Colon Rectum. 2019;62(6):684\u201393. https:\/\/doi.org\/10.1097\/DCR.0000000000001367.","journal-title":"Dis Colon Rectum."},{"issue":"1","key":"12097_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1245\/s10434-017-6037-6","volume":"25","author":"CEL Klaver","year":"2018","unstructured":"Klaver CEL, van Huijgevoort NCM, de Buck van Overstraeten A, et al. Locally advanced colorectal cancer: true peritoneal tumor penetration is associated with peritoneal metastases. Ann Surg Oncol. 2018;25(1):212\u201320. https:\/\/doi.org\/10.1245\/s10434-017-6037-6.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"12097_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","volume":"20","author":"C Honor\u00e9","year":"2013","unstructured":"Honor\u00e9 C, Go\u00e9r\u00e9 D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20(1):183\u201392. https:\/\/doi.org\/10.1245\/s10434-012-2473-5.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"12097_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1111\/codi.15880","volume":"23","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Qin X, Chen W, et al. Risk factors for developing peritoneal metastases after curative surgery for colorectal cancer: a systematic review and meta-analysis. Color Dis. 2021;23(11):2846\u201358. https:\/\/doi.org\/10.1111\/codi.15880.","journal-title":"Color Dis."},{"key":"12097_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/J.IJSU.2017.08.586","volume":"46","author":"RA Agha","year":"2017","unstructured":"Agha RA, Borrelli MR, Vella-Baldacchino M, et al. The STROCSS statement: strengthening the reporting of cohort studies in surgery. Int J Surg. 2017;46:198\u2013202. https:\/\/doi.org\/10.1016\/J.IJSU.2017.08.586.","journal-title":"Int J Surg."},{"issue":"3","key":"12097_CR24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/CODI.15415","volume":"23","author":"ASF Olsen","year":"2021","unstructured":"Olsen ASF, Gundestrup AK, Kleif J, Thanon T, Bertelsen CA. Accuracy of preoperative staging with multidetector computed tomography in colon cancer. Color Dis. 2021;23(3):680\u20138. https:\/\/doi.org\/10.1111\/CODI.15415.","journal-title":"Color Dis."},{"issue":"1","key":"12097_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02215-4","volume":"19","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Han Z, Dou F, Yan T. Pre-colectomy location and TNM staging of colon cancer by the computed tomography colonography: a diagnostic performance study. World J Surg Oncol. 2021;19(1):1\u201313. https:\/\/doi.org\/10.1186\/s12957-021-02215-4.","journal-title":"World J Surg Oncol."},{"key":"12097_CR26","volume-title":"AJCC cancer staging manual","author":"M Amin","year":"2018","unstructured":"Amin M, Edge SB, Greene F. AJCC cancer staging manual. 8th edn. Berlin: Springer; 2018.","edition":"8"},{"issue":"2","key":"12097_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"issue":"5","key":"12097_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis."},{"issue":"2","key":"12097_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/01.sla.0000152019.14741.97","volume":"241","author":"D Marrelli","year":"2005","unstructured":"Marrelli D, De Stefano A, De Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241(2):247\u201355. https:\/\/doi.org\/10.1097\/01.sla.0000152019.14741.97.","journal-title":"Ann Surg."},{"issue":"8","key":"12097_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","volume":"40","author":"YRBM Van Gestel","year":"2014","unstructured":"Van Gestel YRBM, Thomassen I, Lemmens VEPP, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.001.","journal-title":"Eur J Surg Oncol."},{"issue":"27","key":"12097_CR31","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","volume":"25","author":"L Rodr\u00edguez-Ortiz","year":"2019","unstructured":"Rodr\u00edguez-Ortiz L, Arjona-S\u00e1nchez \u00c1, Rufi\u00e1n-Pe\u00f1a S, et al. Colorectal peritoneal metastases: optimal management review. World J Gastroenterol. 2019;25(27):3484\u2013502. https:\/\/doi.org\/10.3748\/wjg.v25.i27.3484.","journal-title":"World J Gastroenterol."},{"key":"12097_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/codi.15368","author":"A Bhatt","year":"2020","unstructured":"Bhatt A, Rousset P, Benzerdjeb N, et al. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases\u2014implications on the preoperative estimation of the peritoneal cancer index (PCI). Color Dis. 2020. https:\/\/doi.org\/10.1111\/codi.15368.","journal-title":"Color Dis."},{"issue":"6","key":"12097_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/JSO.21601","volume":"102","author":"J Esquivel","year":"2010","unstructured":"Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565\u201370. https:\/\/doi.org\/10.1002\/JSO.21601.","journal-title":"J Surg Oncol."},{"issue":"5","key":"12097_CR34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1245\/s10434-016-5732-z","volume":"24","author":"H Nagata","year":"2017","unstructured":"Nagata H, Ishihara S, Hata K, et al. Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol. 2017;24(5):1269\u201380. https:\/\/doi.org\/10.1245\/s10434-016-5732-z.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"12097_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/DCR.0000000000001002","volume":"61","author":"S Mayanagi","year":"2018","unstructured":"Mayanagi S, Kashiwabara K, Honda M, et al. Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis Colon Rectum. 2018;61(7):803\u20138. https:\/\/doi.org\/10.1097\/DCR.0000000000001002.","journal-title":"Dis Colon Rectum."},{"issue":"4","key":"12097_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0035-1564431","volume":"28","author":"A Nadler","year":"2015","unstructured":"Nadler A, McCart JA, Govindarajan A. Peritoneal carcinomatosis from colon cancer: a systematic review of the data for cytoreduction and intraperitoneal chemotherapy. Clin Colon Rectal Surg. 2015;28(4):234\u201346. https:\/\/doi.org\/10.1055\/s-0035-1564431.","journal-title":"Clin Colon Rectal Surg."},{"issue":"05","key":"12097_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-0040-1713742","volume":"33","author":"D Cortes-Guiral","year":"2020","unstructured":"Cortes-Guiral D, Glehen O. Expanding uses of HIPEC for locally advanced colorectal cancer: a European perspective. Clin Colon Rectal Surg. 2020;33(05):253\u20137. https:\/\/doi.org\/10.1055\/s-0040-1713742.","journal-title":"Clin Colon Rectal Surg."},{"issue":"2","key":"12097_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/SLA.0b013e31822638f6","volume":"254","author":"D Elias","year":"2011","unstructured":"Elias D, Honor\u00e9 C, Dumont F, et al. Results of systematic second-look surgery plus hipec in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254(2):289\u201393. https:\/\/doi.org\/10.1097\/SLA.0b013e31822638f6.","journal-title":"Ann Surg."},{"issue":"23","key":"12097_CR39","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","volume":"29","author":"V Valentini","year":"2011","unstructured":"Valentini V, Van Stiphout RGPM, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163\u201372. https:\/\/doi.org\/10.1200\/JCO.2010.33.1595.","journal-title":"J Clin Oncol."},{"issue":"8","key":"12097_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.20.02553","volume":"39","author":"MR Weiser","year":"2021","unstructured":"Weiser MR, Hsu M, Bauer PS, et al. Clinical calculator based on molecular and clinicopathologic characteristics predicts recurrence following resection of stage I\u2013III colon cancer. J Clin Oncol. 2021;39(8):911\u20139. https:\/\/doi.org\/10.1200\/JCO.20.02553.","journal-title":"J Clin Oncol."},{"issue":"3","key":"12097_CR41","doi-asserted-by":"publisher","first-page":"e513","DOI":"10.1016\/j.clcc.2018.03.011","volume":"17","author":"C Kim","year":"2018","unstructured":"Kim C, Kim WR, Kim KY, et al. Predictive nomogram for recurrence of stage I colorectal cancer after curative resection. Clin Colorectal Cancer. 2018;17(3):e513\u20138. https:\/\/doi.org\/10.1016\/j.clcc.2018.03.011.","journal-title":"Clin Colorectal Cancer."},{"issue":"1","key":"12097_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S10120-021-01268-4","volume":"2021","author":"A Agnes","year":"2021","unstructured":"Agnes A, Biondi A, Persiani R, et al. Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer. Gastric Cancer. 2021;2021(1):1\u201311. https:\/\/doi.org\/10.1007\/S10120-021-01268-4.","journal-title":"Gastric Cancer"},{"issue":"4","key":"12097_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/codi.13219","volume":"18","author":"J Segelman","year":"2016","unstructured":"Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. Color Dis. 2016;18(4):378\u201385. https:\/\/doi.org\/10.1111\/codi.13219.","journal-title":"Color Dis."},{"issue":"9","key":"12097_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamasurg.2015.1525","volume":"150","author":"R Amri","year":"2015","unstructured":"Amri R, Bordeianou LG, Sylla P, Berger DL. Association of radial margin positivity with colon cancer. JAMA Surg. 2015;150(9):890\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2015.1525.","journal-title":"JAMA Surg."},{"issue":"3","key":"12097_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-2005-916279","volume":"18","author":"RG Landmann","year":"2005","unstructured":"Landmann RG, Weiser MR. Surgical management of locally advanced and locally recurrent colon cancer. Clin Colon Rectal Surg. 2005;18(3):182\u20139. https:\/\/doi.org\/10.1055\/s-2005-916279.","journal-title":"Clin Colon Rectal Surg."},{"issue":"12","key":"12097_CR46","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(16)30500-9.","journal-title":"Lancet Oncol."},{"issue":"12","key":"12097_CR47","doi-asserted-by":"publisher","first-page":"e1968","DOI":"10.1002\/ONCO.13521","volume":"25","author":"Y Li","year":"2020","unstructured":"Li Y, Yao Q, Zhang L, et al. immunohistochemistry-based consensus molecular subtypes as a prognostic and predictive biomarker for adjuvant chemotherapy in patients with stage II colorectal cancer. Oncologist. 2020;25(12):e1968\u201379. https:\/\/doi.org\/10.1002\/ONCO.13521.","journal-title":"Oncologist."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T22:11:30Z","timestamp":1665439890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["12097"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12097-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Antonino Spinelli acted as a consultant\/speaker for Johnson&Johnson and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}